Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Innovation Would Be the Best Method to Fight Generics' Primacy in the Latin American Cardiovascular Drugs Markets
- BUENOS AIRES, Argentina -- Latin American countries, due to their desire to mimic the lifestyles of developed countries, are increasingly falling prey to cardiovascular diseases CVDs. This situation is providing valuable opportunities to pharmaceutical companies to develop drugs that can reduce drug interactions and offer better efficacy and safety profile....
- Research articles 2008-04-16
- Product Life Cycle Management Key to Sustaining Revenue Growth in European Gastroenterology Therapeutics Market
- LONDON -- The European gastroenterology therapeutics market is in the maturity phase and is highly competitive. Brand recognition and product efficacy drive product acceptance in the market. Downward price pressures caused by cost control measures adopted by European governments and the extensive availability of generics are negatively affecting overall revenue...
- Research articles 2007-11-26
- Growing Demand for Inexpensive, Effective Drugs and Continuing Patent Expiries Provide Growth Prospects for the European Generics Market.(Industry overview)
- LONDON, July 12 /PRNewswire/ -- With an ageing population and expensive drugs driving healthcare costs upwards, generic medicines are gaining significance in Europe. The governments are under tremendous pressure to reduce healthcare expenditure. In this scenario, generics are widely regarded as the...
- Research articles 2007-07-12
- Teva is The Clear Market Leader Since Its 2006 Purchase of IVAX States New Report Opportunities and Challenges for Generic Drugs In The UK 2007.
- M2 PRESSWIRE-2 July 2007-Research and Markets: Teva is The Clear Market Leader Since Its 2006 Purchase of IVAX States New Report Opportunities and Challenges for Generic Drugs In The UK 2007C1994-2007 M2 COMMUNICATIONS LTD RDATE:04072007 Dublin - Research and Markets ...
- Research articles 2007-07-02
- PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study and Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals Conference.
- M2 PRESSWIRE-30 April 2007-U.S. Equity News: PDL BioPharma Advances NuvionR Into Second Pivotal Study and Celgene Corporation Will Present at the UBS Global Generic and Specialty Pharmaceuticals ConferenceC1994-2007 M2 COMMUNICATIONS LTD RDATE:30042007 City of Industry, CA - Biotechnology industry alert provided...
- Research articles 2007-04-30
- New Study Reveals Generic Drugs Continue Entering Market as Competition from Authorized Generics Increases
- To: HEALTH/MEDICAL EDITORSContact: Jennifer Page of PhRMA, +1-202-835-3460 WASHINGTON, April 19 /PRNewswire-USNewswire/ -- According to a new study by researchers at the Massachusetts Institute of Technology's MIT School of Management and Analysis Group Inc., there is no evidence that the recent increase in prevalence of authorized generics has resulted in...
- Research articles 2007-04-19
- Generic Cholesterol Drugs Vital to Helping Consumers, Nation Lower Health-Care Costs
- To: MEDICAL EDITORSContact: Susan Herold or Steve Findlay of Consumers Union, +1-202- 462-6262 WASHINGTON, April 3 /PRNewswire-USNewswire/ -- As the maker of Lipitor reportedly urges doctors to carefully consider prescribing generics to lower cholesterol, Consumer Reports Best Buy Drugs reminds consumers that generic statins are as effective as high- priced...
- Research articles 2007-04-03
- Rising Pharmaceutical Expenditures and an Ageing Population Propel Growth of the European Generics Market.(Industry overview)
- LONDON, February 13 /PRNewswire/ -- An ageing population and rising drug costs are underlining the increasingly critical role of cost-effective generic medicines. Simultaneously, the highly competitive generics industry is pressurising the mainstream pharmaceutical sector to develop innovative drugs. "An...
- Research articles 2007-02-13
- Prescriptions for Cholesterol Drugs Rise with New Generics
- To: HEALTH/MEDICAL EDITORSContact: Susan Herold of Consumers Union, +1-202-462-6262, sherold@consumer.org WASHINGTON, Feb. 13 /PRNewswire-USNewswire/ -- Prescriptions for the cholesterol-lowering medicines known as statins rose by an average of 500,000 a month between October 2005 and December 2006, according to a new analysis by Consumers Union and Consumer Reports Best Buy...
- Research articles 2007-02-13
- Abraxis BioScience Launches Ondansetron Injection, USP
- LOS ANGELES -- Abraxis BioScience, Inc. (NASDAQ: ABBI), an integrated, global biopharmaceutical company, today announced that it has launched Ondansetron Injection, USP, the generic equivalent of GlaxoSmithKline's Zofran([R]) Injection. According to IMS, sales in 2005 of ondansetron in the United States exceeded $587 million. The company markets ondansetron in AP-rated...
- Research articles 2007-01-04
- Opening a path for biotech generics
- A debate has raged for years within the pharmaceutical industry, among generic-drug-makers, and on Capitol Hill about whether to allow lower-cost generic or "follow-on" versions of biotech drugs. With some biologic drugs costing up to $100,000 a year for rare disorders, generics offer the promise of lower costs. The stakes...
- Research articles 2006-09-19
- Lipitor faces first big generic hurdle
- As employers look to cut prescription drug costs, some consumers are finding Lipitor, the world's most popular drug, harder and more expensive to get. The leading anti-cholesterol drug is under pressure as employers push for use of lower-cost generics. In June, No. 2 anti-cholesterol drug Zocor went generic, setting...
- Research articles 2006-07-10
- Kroner suit aims to overturn deal on generic form of Plavix
- CINCINNATI -- Kroger Co. has gone to court to block a deal that would delay generic alternatives to the popular blood-thinning drug Plavix. Bristol-Myers Squibb Co. and Sanofi-Aventis had reached a settlement with generic drug maker Apotex Inc. over a patent dispute regarding Plavix, which is the world's No....
- Research articles 2006-04-24
- Prasco Laboratories: President Bush 2007 Budget Request Calls for Elimination of ''Best Price''; Proposal Would Remove Barrier to Pro-Consumer, Pro-Taxpayer Expansion of Authorized Generics
- CINCINNATI -- As a part of his FY2007 budget, President Bush has proposed that Congress "eliminate best price practices from Medicaid prescription drug rebates and replace it with a budget neutral flat rebate."a Comparing best price practices with a price floor, the proposal describes best price as "interfering with the...
- Research articles 2006-02-10
- The reform of the NHS in Portugal
- Abstract The objective of this article is to describe the Portuguese National Healthcare Service, giving a special emphasis to the recent reforms that have been introduced since the beginning of 2002. Its main argument is that there are two different but connected rationales that underpin the orientation of the...
- Research articles 2005-09-22
- Indian patent law will blight fight against HIV/AIDS: UNAIDS
- GENEVA AFP — The UN official leading the global fight against HIV/AIDS warned that India's recent law banning the copy of patented medicines will become a major obstacle in fighting the rising tide of the disease in the country. "It's not a problem for today or the next few...
- Research articles 2005-04-14
- Cost Cutting Measures and Patent Expirations to Propel the European Generics and Biogenerics Market.
- LONDON, October 19 /PRNewswire/ -- The upcoming spate of patent expirations bodes well for the European generics market. The growing loss of patent protection on blockbuster brands over the next few years, coupled with the rising need to contain spiralling healthcare costs, is...
- Research articles 2004-10-19
- Cost Cutting in Healthcare Expanding Markets for Generic and Biogeneric Products
- PALO ALTO, Calif. -- The market for generic and biogeneric drugs is poised for rapid growth due to patent expirations for many blockbuster products leading to their mass genericization. There has also been a conscious move in developed societies to increase the use of generic and biogeneric products for containing...
- Research articles 2004-09-13
- Biotech
- Novartis subsidiary Sandoz estimates that by 2007, biotech drugs with more than $16 million in sales will go off patent. In fact, the European patent for synthetic human hormone EPO expires this December. However, most biotech companies estimate that biogenerics are four to seven years away from market. Besides the...
- Research articles 2004-06-15
- Consumers, states challenge federal ban on drug imports.
- In the midst of an election-year maelstrom over high prescription drug prices, aim elderly Chicago-area couple has sued the FDA and the U.S. Department of Health and Human Services HHS to permit the legalized import of cheaper prescription drugs from Canada. (Andrews v. Dep't of Health...
- Research articles 2004-06-01
- << Previous
- page 1 of 5
- Next >>
Content Types
Refining Tags
- Healthcare (14 results)
- Marketing (13 results)
- Government (13 results)
- Finance (10 results)
- Sales (10 results)
- Benefits (9 results)
- Software (9 results)
- Blue Cross Blue Shield (9 results)
- Pharmaceutical Company (8 results)
- Jim Edwards (8 results)
- Frost & Sullivan (7 results)
- Human Resources (7 results)
- Branding (7 results)
- Patient (6 results)
- Call Transcript (6 results)
- Earnings (6 results)
- prescription (6 results)
- Seeking Alpha (6 results)
- Zocor (6 results)
- FDA (6 results)
- Sales Strategy (5 results)
- brand (5 results)
- Strategy (5 results)
- Revenue (5 results)
- Advertisement (4 results)
- Biotechnology (4 results)
- U.S. (4 results)
- Pfizer Inc. (4 results)
- Manufacturing (4 results)
- Patent (4 results)
- Health Care (4 results)
- pharmacy (4 results)
- Consumer Reports (3 results)
- Business Operations (3 results)
- IVAX Corp. (3 results)
- Vertical Industries (3 results)
- John Maas (3 results)
- FTC (3 results)
- Lipitor (3 results)
- benefit (3 results)
- insurance company (3 results)
- PBM (3 results)
- U.S. Congress (3 results)
- Workforce Management (3 results)
- Wal-Mart Stores Inc. (3 results)
- Merck & Co. Inc. (3 results)
